C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer

Eesults from the ASCENT trial

Tomasz (Tom) Beer, Alshad S. Lalani, Stella Lee, Motomi (Tomi) Mori, Kristine M. Eilers, John G. Curd, W. David Henner, Christopher Ryan, Peter Venner, J. Dean Ruether, Kim N. Chi

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

BACKGROUND. Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy. METHODS. Baseline plasma samples were stored (-80°C) from 160 of 250 patients enrolled in the AIPC Study of Calcitriol ENhancing Taxotere (ASCENT) trial, a randomized, placebo-controlled trial comparing weekly docetaxel plus high-dose calcitriol with weekly docetaxel. Multiplex immunoassays measured 16 cytokine, chemokine, cardiovascular, or inflammatory markers. The Cox proportional hazards model was used to assess associations between baseline biomarkers, clinical characteristics, and survival. Logistic regression was used for analyses of associations with prostate-specific antigen (PSA) decline. RESULTS. C-reactive protein (CRP) was found to be significantly predictive of a shorter overall survival (hazards ratio [HR] of 1.41 for each natural logarithm [In] [CRP] increase; 95% confidence interval [95% CI], 1.20-1.65 [P <.0001]). When CRP (continuous) was entered into a multivariate model using 13 baseline clinical variables, only elevated CRP remained a significant predictor (P <.0001) of shorter overall survival. When categorized as normal (≤8 mg/L) or abnormal (>8 mg/L), elevated CRP was found to be a significant predictor of shorter overall survival (HR of 2.96; 95% CI, 1.52-5.77 [P = .001]), as was hemoglobin (P = .007). Elevated CRP was also associated with a lower probability of PSA decline (odds ratio of 0.74 for each In(CRP) increase; 95% CI, 0.60-0.92 [P = .007]). CONCLUSIONS. Elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy.

Original languageEnglish (US)
Pages (from-to)2377-2383
Number of pages7
JournalCancer
Volume112
Issue number11
DOIs
StatePublished - Jun 1 2008

Fingerprint

docetaxel
Calcitriol
C-Reactive Protein
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Survival
Confidence Intervals
Blood Proteins
Inflammation
Chemokines
Immunoassay
Proportional Hazards Models
VA 061
Neoplasms
Carcinogenesis
Randomized Controlled Trials
Biomarkers
Logistic Models
Odds Ratio

Keywords

  • C-reactive protein
  • Inflammation
  • Prognostic factors
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer : Eesults from the ASCENT trial. / Beer, Tomasz (Tom); Lalani, Alshad S.; Lee, Stella; Mori, Motomi (Tomi); Eilers, Kristine M.; Curd, John G.; Henner, W. David; Ryan, Christopher; Venner, Peter; Ruether, J. Dean; Chi, Kim N.

In: Cancer, Vol. 112, No. 11, 01.06.2008, p. 2377-2383.

Research output: Contribution to journalArticle

Beer, TT, Lalani, AS, Lee, S, Mori, MT, Eilers, KM, Curd, JG, Henner, WD, Ryan, C, Venner, P, Ruether, JD & Chi, KN 2008, 'C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Eesults from the ASCENT trial', Cancer, vol. 112, no. 11, pp. 2377-2383. https://doi.org/10.1002/cncr.23461
Beer, Tomasz (Tom) ; Lalani, Alshad S. ; Lee, Stella ; Mori, Motomi (Tomi) ; Eilers, Kristine M. ; Curd, John G. ; Henner, W. David ; Ryan, Christopher ; Venner, Peter ; Ruether, J. Dean ; Chi, Kim N. / C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer : Eesults from the ASCENT trial. In: Cancer. 2008 ; Vol. 112, No. 11. pp. 2377-2383.
@article{8989fe0199a84e01b9d16e6e8def9c41,
title = "C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Eesults from the ASCENT trial",
abstract = "BACKGROUND. Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy. METHODS. Baseline plasma samples were stored (-80°C) from 160 of 250 patients enrolled in the AIPC Study of Calcitriol ENhancing Taxotere (ASCENT) trial, a randomized, placebo-controlled trial comparing weekly docetaxel plus high-dose calcitriol with weekly docetaxel. Multiplex immunoassays measured 16 cytokine, chemokine, cardiovascular, or inflammatory markers. The Cox proportional hazards model was used to assess associations between baseline biomarkers, clinical characteristics, and survival. Logistic regression was used for analyses of associations with prostate-specific antigen (PSA) decline. RESULTS. C-reactive protein (CRP) was found to be significantly predictive of a shorter overall survival (hazards ratio [HR] of 1.41 for each natural logarithm [In] [CRP] increase; 95{\%} confidence interval [95{\%} CI], 1.20-1.65 [P <.0001]). When CRP (continuous) was entered into a multivariate model using 13 baseline clinical variables, only elevated CRP remained a significant predictor (P <.0001) of shorter overall survival. When categorized as normal (≤8 mg/L) or abnormal (>8 mg/L), elevated CRP was found to be a significant predictor of shorter overall survival (HR of 2.96; 95{\%} CI, 1.52-5.77 [P = .001]), as was hemoglobin (P = .007). Elevated CRP was also associated with a lower probability of PSA decline (odds ratio of 0.74 for each In(CRP) increase; 95{\%} CI, 0.60-0.92 [P = .007]). CONCLUSIONS. Elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy.",
keywords = "C-reactive protein, Inflammation, Prognostic factors, Prostate cancer",
author = "Beer, {Tomasz (Tom)} and Lalani, {Alshad S.} and Stella Lee and Mori, {Motomi (Tomi)} and Eilers, {Kristine M.} and Curd, {John G.} and Henner, {W. David} and Christopher Ryan and Peter Venner and Ruether, {J. Dean} and Chi, {Kim N.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1002/cncr.23461",
language = "English (US)",
volume = "112",
pages = "2377--2383",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer

T2 - Eesults from the ASCENT trial

AU - Beer, Tomasz (Tom)

AU - Lalani, Alshad S.

AU - Lee, Stella

AU - Mori, Motomi (Tomi)

AU - Eilers, Kristine M.

AU - Curd, John G.

AU - Henner, W. David

AU - Ryan, Christopher

AU - Venner, Peter

AU - Ruether, J. Dean

AU - Chi, Kim N.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - BACKGROUND. Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy. METHODS. Baseline plasma samples were stored (-80°C) from 160 of 250 patients enrolled in the AIPC Study of Calcitriol ENhancing Taxotere (ASCENT) trial, a randomized, placebo-controlled trial comparing weekly docetaxel plus high-dose calcitriol with weekly docetaxel. Multiplex immunoassays measured 16 cytokine, chemokine, cardiovascular, or inflammatory markers. The Cox proportional hazards model was used to assess associations between baseline biomarkers, clinical characteristics, and survival. Logistic regression was used for analyses of associations with prostate-specific antigen (PSA) decline. RESULTS. C-reactive protein (CRP) was found to be significantly predictive of a shorter overall survival (hazards ratio [HR] of 1.41 for each natural logarithm [In] [CRP] increase; 95% confidence interval [95% CI], 1.20-1.65 [P <.0001]). When CRP (continuous) was entered into a multivariate model using 13 baseline clinical variables, only elevated CRP remained a significant predictor (P <.0001) of shorter overall survival. When categorized as normal (≤8 mg/L) or abnormal (>8 mg/L), elevated CRP was found to be a significant predictor of shorter overall survival (HR of 2.96; 95% CI, 1.52-5.77 [P = .001]), as was hemoglobin (P = .007). Elevated CRP was also associated with a lower probability of PSA decline (odds ratio of 0.74 for each In(CRP) increase; 95% CI, 0.60-0.92 [P = .007]). CONCLUSIONS. Elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy.

AB - BACKGROUND. Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy. METHODS. Baseline plasma samples were stored (-80°C) from 160 of 250 patients enrolled in the AIPC Study of Calcitriol ENhancing Taxotere (ASCENT) trial, a randomized, placebo-controlled trial comparing weekly docetaxel plus high-dose calcitriol with weekly docetaxel. Multiplex immunoassays measured 16 cytokine, chemokine, cardiovascular, or inflammatory markers. The Cox proportional hazards model was used to assess associations between baseline biomarkers, clinical characteristics, and survival. Logistic regression was used for analyses of associations with prostate-specific antigen (PSA) decline. RESULTS. C-reactive protein (CRP) was found to be significantly predictive of a shorter overall survival (hazards ratio [HR] of 1.41 for each natural logarithm [In] [CRP] increase; 95% confidence interval [95% CI], 1.20-1.65 [P <.0001]). When CRP (continuous) was entered into a multivariate model using 13 baseline clinical variables, only elevated CRP remained a significant predictor (P <.0001) of shorter overall survival. When categorized as normal (≤8 mg/L) or abnormal (>8 mg/L), elevated CRP was found to be a significant predictor of shorter overall survival (HR of 2.96; 95% CI, 1.52-5.77 [P = .001]), as was hemoglobin (P = .007). Elevated CRP was also associated with a lower probability of PSA decline (odds ratio of 0.74 for each In(CRP) increase; 95% CI, 0.60-0.92 [P = .007]). CONCLUSIONS. Elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy.

KW - C-reactive protein

KW - Inflammation

KW - Prognostic factors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=52049085538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049085538&partnerID=8YFLogxK

U2 - 10.1002/cncr.23461

DO - 10.1002/cncr.23461

M3 - Article

VL - 112

SP - 2377

EP - 2383

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -